XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Operations (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:                
Research and development $ 13,837,650     $ 4,123,538     $ 29,885,874 $ 10,307,142
General and administrative 1,025,621     2,361,299     4,706,813 7,403,817
Total operating expenses 14,863,271     6,484,837     34,592,687 17,710,959
Operating loss (14,863,271)     (6,484,837)     (34,592,687) (17,710,959)
Other income:                
Interest income 146,655     52,886     601,768 108,559
Total other income 146,655     52,886     601,768 108,559
Loss before income taxes (14,716,616)     (6,431,951)     (33,990,919) (17,602,400)
Income tax expense (benefit) 0     0     0 0
Net loss $ (14,716,616) $ (9,537,122) $ (9,737,181) $ (6,431,951) $ (5,936,386) $ (5,234,063) $ (33,990,919) $ (17,602,400)
Basic loss per common share $ (1.63)     $ (0.79)     $ (3.90) $ (2.16)
Diluted loss per common share $ (1.63)     $ (0.79)     $ (3.90) $ (2.16)
Weighted average number of common shares outstanding, basic 9,012,273     8,163,923     8,722,518 8,161,787
Weighted average number of common shares outstanding, diluted 9,012,273     8,163,923     8,722,518 8,161,787
As Reported                
Operating expenses:                
Research and development       $ 5,313,033       $ 14,938,532
General and administrative       2,361,299       7,403,817
Total operating expenses       7,674,332       22,342,349
Operating loss       (7,674,332)       (22,342,349)
Other income:                
Interest income       52,886       108,559
Total other income       52,886       108,559
Loss before income taxes       (7,621,446)       (22,233,790)
Net loss       $ (7,621,446)       $ (22,233,790)
Basic loss per common share       $ (0.93)       $ (2.72)
Diluted loss per common share       $ (0.93)       $ (2.72)
Weighted average number of common shares outstanding, basic       8,163,923       8,161,787
Weighted average number of common shares outstanding, diluted       8,163,923       8,161,787
Restatement Impacts                
Operating expenses:                
Research and development       $ (1,189,495)       $ (4,631,390)
Total operating expenses       (1,189,495)       (4,631,390)
Operating loss       1,189,495       4,631,390
Other income:                
Loss before income taxes       1,189,495       4,631,390
Net loss       $ 1,189,495       $ 4,631,390